Knowledge Library

WuXi Biology Fact Sheet

Expertise in all major disease areas and all major target classes, enabling discovery for all therapeutic modalities World class antiviral platform with an unequalled service capability and capacity in HBV and other viral diseases A global leader in DNA Encoded Library (DEL) screening, with innovative business models CAP-certified pathology and FACS capabilities supporting clinical biomarker …Read More >

Resource Type: Brochure Latest Science
Resource Topic: DRUG DISCOVERY AND INNOVATION TECHNOLOGY PLATFORMS THERAPEUTIC AREAS

VIEW

Targeted Protein Degradation

WuXi AppTec utilizes state-of-the-art techniques to support drug discovery teams focused on targeted protein degradation. Our services include a broad range of ligand-finding methods, such as DEL, fragment screening, ASMS, and virtual screening. We provide custom linker design and complex synthesis for new linkers and E3 ligase ligands. To support lead optimization efforts, our platform …Read More >

Resource Type: Brochure Latest Science
Resource Topic: Biochemical Assays Biophysical Assays Cell-based Assays Mass Spectrometry-based Assays Oncology Small Molecules Structural Biology Targeted Protein Degradation

VIEW

In Vitro Imaging Services

Offering a comprehensive platform of in vitro imaging-based assays to screen compounds for cancer, inflammation, and autoimmune diseases. Our services include: Imaging assays for cell proliferation and apoptosis Imaging assays for cell cycle analysis Cell-based functional assays, including: Antibody internalization Live-cell immunocytochemistry Cellular movement and morphology monitoring Assays for 3D cell models, including: Spheroid growth …Read More >

Resource Type: Latest Science Presentation
Resource Topic: Biomarkers Cell-based Assays Hit-to-Lead Lead Optimization Oncology Phenotypic Assays Target Identification and Validation

VIEW

CDK4/6 Inhibitor Resistant Breast Cancer Models

Leverage our extensive panel of CDK4/6 inhibitor resistant breast cancer models, including:  In vitro induced Palbociclib resistant MCF-7 cell line In vivo induced Palbociclib resistant MCF-7 model In vivo induced Abemaciclib resistant MCF-7 model In vivo induced Ribociclib resistant MCF-7 model

Resource Type: Latest Science Presentation
Resource Topic: Cell-based Assays Oncology Target-Specific Assays Tumor Models

VIEW

OncoWuXi Newsletter December 2022

Resource Type: Latest Science Newsletter
Resource Topic: Autoimmune and Inflammatory Diseases Biochemical Assays Biomarkers Candidate Selection Cell-based Assays CRISPR/Cas9 DRUG DISCOVERY AND INNOVATION Hit Finding Hit-to-Lead Immunology Lead Optimization Oncology Phenotypic Assays Rare Diseases Target Identification and Validation Tumor Models

VIEW

Discovery Newsletter Special New Year Edition 2023

Resource Type: Latest Science Newsletter
Resource Topic: Biophysical Assays Central Nervous System & Pain Discovery Chemistry DNA-Encoded Library (DEL) Hit-to-Lead in silico services Lead Optimization Quantum Mechanics Small Molecules Target Identification and Validation Targeted Protein Degradation

VIEW

Introduction into Fragment Based Drug Discovery

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification in the drug discovery process. Fragments are small molecules with a low molecular weight, smaller than lead molecules or druglike molecules. The FBDD technology is based on identifying small chemical fragments, which bind to the biological target …Read More >

Resource Type: Latest Science Webinar
Resource Topic: Discovery Chemistry Fragment-Based Drug Discovery Hit Finding Hit-to-Lead Screening Libraries Small Molecules Target Identification and Validation

VIEW

Discovery Newsletter November 2022

Resource Type: Latest Science Newsletter
Resource Topic: CAR-T Cell Cell-based Assays Chemical Biology and Proteomics Discovery Chemistry DRUG DISCOVERY AND INNOVATION in vitro biology Oligonucleotides Oncolytic Viruses Safety and Early Toxicity Small Molecules Target Identification and Validation Target-Specific Assays

VIEW

PD-1 Blockade Protein in 4th Generation Armored CAR-T Cells Enhances Cytotoxicity Effect with in vitro Re-challenge System

Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA). CAR-T cell therapy have demonstrated remarkable success with hematological malignancies. However, limited headway has been made towards solid tumor, due to various challenges, including recognition of tumor-specific antigen trafficking and penetration, localization and survival within …Read More >

Resource Type: Latest Science Poster
Resource Topic: Antibodies Biomarkers CAR-T Cell Cell Therapies Cell-based Assays Cells and Protein Science Oncology Target Identification and Validation

VIEW


Resource Topics